Ivonescimab and Cadonilimab Phase III Results to Be Presented at ESMO Congress 2025

Ivonescimab HARMONi-6 Results Selected for ESMO 2025 LBA; Final Phase III Results of Cadonilimab as First-Line Therapy for Advanced Gastric Cancer to Be Published as an Oral Presentation

HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) is excited to announce that the Late-Breaking Abstract (LBA) from the registrational Phase III clinical study (AK112-306/HARMONi-6 study) of ivonescimab, a globally first-in-class bispecific antibody targeting PD-1 and VEGF, will…

Ivonescimab and Cadonilimab Phase III Results to Be Presented at ESMO Congress 2025

The results of two significant clinical studies in onco […] The post Ivonescimab and Cadonilimab Phase III Results to Be Presented at ESMO Congress 2025 first appeared on GeneOnline News. The post Ivonescimab and Cadonilimab Phase III Results to Be Presented at ESMO Congress 2025 appeared first on GeneOnline News.